This Article Full Text Full Text (PDF) All Versions of this Article: 117/7/886    most recent CIRCULATIONAHA.107.759167v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Angioplasty Heart Attack Related Collections Cardiovascular Pharmacology Catheter-based coronary interventions: stents Acute myocardial infarction Related Article

(Circulation. 2008;117:886-896.)
© 2008 American Heart Association, Inc.

Coronary Heart Disease

Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

Direct Inhibition of -Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators

A complete list of the members of the Direct Inhibition of -Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators appears in the Appendix at the end of this article. All Steering Committee members were part of the Writing Committee.

Correspondence to Matthew T. Roe, Duke Clinical Research Institute, 2400 Pratt St, Room 7035, Durham, NC 27705. E-mail matthew.roe{at}duke.edu

Received September 20, 2007. accepted December 14, 2007.

Background— KAI-9803, a -protein kinase C inhibitor, has been shown to ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI).

Methods and Results— Direct Inhibition of -Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) was a "first-in-human," dose-escalation study that evaluated the safety, tolerability, and activity of KAI-9803 for patients with acute anterior ST-segment elevation MI undergoing primary percutaneous coronary intervention. Patients who presented within 6 hours of symptom onset and had an occluded left anterior descending infarct artery on angiography were randomized in a 2:1 fashion to receive 1 of 4 doses of KAI-9803 (cohort 1, 0.05 mg; cohort 2, 0.5 mg; cohort 3, 1.25 mg; cohort 4, 5.0 mg) versus blinded concurrent placebo delivered in 2 divided doses via intracoronary injection before and after reestablishment of antegrade epicardial flow with percutaneous coronary intervention. Safety and biomarker end points were assessed. Overall, 154 patients were randomized and treated with study drug (37 in cohort 1, 38 in cohort 2, 38 in cohort 3, 41 in cohort 4). The incidence of serious adverse events was similar between patients treated with KAI-9803 versus placebo. Other safety end points, including changes in QT intervals and standard laboratory values after study drug administration, were similar between treatment groups. Although the study was not powered to demonstrate efficacy with the biomarker end points assessed, signs of drug activity with KAI-9803 were suggested by trends for consistent, nonsignificant reductions in creatine kinase–MB area under the curve and ST-recovery area under the curve values across all dosing cohorts with KAI-9803 compared with concurrent placebo, and similar trends were demonstrated for improvements in ^99mtechnetium sestamibi infarct size values with active study drug in cohorts 1, 2, and 3.

Conclusions— KAI-9803 had an acceptable safety and tolerability profile when delivered via intracoronary injection during primary percutaneous coronary intervention for ST-segment elevation MI. Signs of potential drug activity were demonstrated with biomarker end points in this small exploratory study, indicating that further testing of KAI-9803 as an adjunctive therapy for ST-segment elevation MI is warranted.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 117: 857-859. [Extract] [Full Text]

This article has been cited by other articles:

				M. Sezer, A. Cimen, E. Aslanger, A. Elitok, B. Umman, Z. Bugra, E. Yormaz, C. Turkmen, I.s. Adalet, Y. Nisanci, et al. Effect of intracoronary streptokinase administered immediately after primary percutaneous coronary intervention on long-term left ventricular infarct size, volumes, and function. J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1065 - 1071. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]

				S. S. Palaniyandi, L. Sun, J. C. B. Ferreira, and D. Mochly-Rosen Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res, May 1, 2009; 82(2): 229 - 239. [Abstract] [Full Text] [PDF]

				D. Atar, P. Petzelbauer, J. Schwitter, K. Huber, B. Rensing, J. D. Kasprzak, C. Butter, L. Grip, P. R. Hansen, T. Suselbeck, et al. Effect of Intravenous FX06 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction: Results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) Trial J. Am. Coll. Cardiol., February 24, 2009; 53(8): 720 - 729. [Abstract] [Full Text] [PDF]

				B. Wu, H. M. Moulton, P. L. Iversen, J. Jiang, J. Li, J. Li, C. F. Spurney, A. Sali, A. D. Guerron, K. Nagaraju, et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer PNAS, September 30, 2008; 105(39): 14814 - 14819. [Abstract] [Full Text] [PDF]

				B. Metzler, Q. Xu, and M. Mayr Letter by Metzler et al Regarding Article, "Intracoronary KAI-9803 as an Adjunct to Primary Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction" Circulation, July 22, 2008; 118(4): e80 - e80. [Full Text] [PDF]